Microcap Adventrx Pharmaceuticals (ANX) shares plummet -56% after the FDA rejects a new...

|By:, SA News Editor

Microcap Adventrx Pharmaceuticals (ANX) shares plummet -56% after the FDA rejects a new application for the development-stage drug maker's lung-cancer treatment Exelbine. The agency says the authenticity of the drug products used in its pivotal bioequivalence trial could not be verified.